I-NS7CAR-T Cell Therapy Ibonisa Isithembiso Sokwelapha i-R/R T-ALL/LBL

Ukushicilelwa kwakamuva kujenali i-Blood kulethe ukunaka okukhulu emandleni e-NS7CAR-T cell therapy ekwelapheni i-T-cell acute lymphoblastic leukemia (R/R T-ALL) kanye ne-T-cell lymphoblastic lymphoma (R/R T). -LBL). Ucwaningo, olwenziwa njengesivivinyo somtholampilo sesigaba 1 (ClinicalTrials.gov: NCT04572308), luhlole ukuphepha nokusebenza kwalokhu kwelashwa okusha.

Ukuhlolwa kwakuhlanganisa iziguli ezine-R/R T-ALL/LBL ezithole amaseli e-NS7CAR-T. Imiphumela yabonisa ukuthi ukwelashwa kwe-NS7CAR-T bekungaphephile kuphela kodwa futhi kubonise umsebenzi ohlaba umxhwele wokulwa nesimila. Iziguli ezelashwe ngamaseli e-NS7CAR-T zibonise izimpendulo ezibalulekile zomtholampilo, okuphakamisa amandla alokhu kwelashwa njengethuluzi elinamandla elimelene nalawa makhaza ayinselele.

Abacwaningi abalandela lolu cwaningo bahlanganisa ithimba lochwepheshe besibhedlela i-Hebei Yanda Lu Daopei kanye ne-Hebei Senlang Biotechnology Co., Ltd. Imiphumela yabo ibonisa ukuthi amaseli e-NS7CAR-T angenziwa ngempumelelo ngaphandle kokuguqulwa kofuzo okwengeziwe ukuze kuvinjelwe ukubonakaliswa kwe-CD7, lula inqubo yokukhiqiza. kanye nokwenza ngcono ukusebenza kokwelashwa.

Le mpumelelo ku-NS7CAR-T cell therapy ihambisana nemizamo eqhubekayo yokuthuthukisa izindlela zokwelapha ezisebenza ngempumelelo ze-T-ALL ne-T-LBL. Inkampani yethu futhi ithuthuka kulo mkhakha ngomkhiqizo wethu ophathelene ne-CAR-T, esikholelwa ukuthi uzohambisana nemiphumela ethembisayo ebonwa ngokwelashwa kwe-NS7CAR-T.

Imiphumela ekhuthazayo yalolu cwaningo ivula indlela yocwaningo olwengeziwe nezivivinyo zomtholampilo ukuze kuqiniswe indima yamaseli e-NS7CAR-T ekwelapheni izifo eziyingozi ze-T-cell ezibuyele emuva noma eziphikayo. Njengoba imininingwane eyengeziwe itholakala, kwethenjwa ukuthi lokhu kwelashwa maduze kuzoba inketho evamile ezigulini ezilwa nalezi zifo ezinolaka.